350 related articles for article (PubMed ID: 32976510)
1. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.
Woodhouse R; Li M; Hughes J; Delfosse D; Skoletsky J; Ma P; Meng W; Dewal N; Milbury C; Clark T; Donahue A; Stover D; Kennedy M; Dacpano-Komansky J; Burns C; Vietz C; Alexander B; Hegde P; Dennis L
PLoS One; 2020; 15(9):e0237802. PubMed ID: 32976510
[TBL] [Abstract][Full Text] [Related]
2. Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors.
Milbury CA; Creeden J; Yip WK; Smith DL; Pattani V; Maxwell K; Sawchyn B; Gjoerup O; Meng W; Skoletsky J; Concepcion AD; Tang Y; Bai X; Dewal N; Ma P; Bailey ST; Thornton J; Pavlick DC; Frampton GM; Lieber D; White J; Burns C; Vietz C
PLoS One; 2022; 17(3):e0264138. PubMed ID: 35294956
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience.
Caputo V; De Falco V; Ventriglia A; Famiglietti V; Martinelli E; Morgillo F; Martini G; Corte CMD; Ciardiello D; Poliero L; De Vita F; Orditura M; Fasano M; Franco R; Caraglia M; Avitabile A; Scalamogna R; Marchi B; Ciardiello F; Troiani T; Napolitano S
Ther Adv Med Oncol; 2022; 14():17588359221096878. PubMed ID: 35547096
[TBL] [Abstract][Full Text] [Related]
4. Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors.
Takeda M; Takahama T; Sakai K; Shimizu S; Watanabe S; Kawakami H; Tanaka K; Sato C; Hayashi H; Nonagase Y; Yonesaka K; Takegawa N; Okuno T; Yoshida T; Fumita S; Suzuki S; Haratani K; Saigoh K; Ito A; Mitsudomi T; Handa H; Fukuoka K; Nakagawa K; Nishio K
Oncologist; 2021 Apr; 26(4):e588-e596. PubMed ID: 33325566
[TBL] [Abstract][Full Text] [Related]
5. Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNA.
Poh J; Ngeow KC; Pek M; Tan KH; Lim JS; Chen H; Ong CK; Lim JQ; Lim ST; Lim CM; Goh BC; Choudhury Y
PLoS One; 2022; 17(4):e0267389. PubMed ID: 35486650
[TBL] [Abstract][Full Text] [Related]
6. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
[No Abstract] [Full Text] [Related]
7. Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA.
Clark TA; Chung JH; Kennedy M; Hughes JD; Chennagiri N; Lieber DS; Fendler B; Young L; Zhao M; Coyne M; Breese V; Young G; Donahue A; Pavlick D; Tsiros A; Brennan T; Zhong S; Mughal T; Bailey M; He J; Roels S; Frampton GM; Spoerke JM; Gendreau S; Lackner M; Schleifman E; Peters E; Ross JS; Ali SM; Miller VA; Gregg JP; Stephens PJ; Welsh A; Otto GA; Lipson D
J Mol Diagn; 2018 Sep; 20(5):686-702. PubMed ID: 29936259
[TBL] [Abstract][Full Text] [Related]
8. Next-Generation Sequencing Concordance Analysis of Comprehensive Solid Tumor Profiling between a Centralized Specialty Laboratory and the Decentralized Personal Genome Diagnostics elio Tissue Complete Kitted Solution.
Deak KL; Jackson JB; Valkenburg KC; Keefer LA; Robinson Gerding KM; Angiuoli SV; Datto MB; McCall SJ
J Mol Diagn; 2021 Oct; 23(10):1324-1333. PubMed ID: 34314880
[TBL] [Abstract][Full Text] [Related]
9. Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies.
Odegaard JI; Vincent JJ; Mortimer S; Vowles JV; Ulrich BC; Banks KC; Fairclough SR; Zill OA; Sikora M; Mokhtari R; Abdueva D; Nagy RJ; Lee CE; Kiedrowski LA; Paweletz CP; Eltoukhy H; Lanman RB; Chudova DI; Talasaz A
Clin Cancer Res; 2018 Aug; 24(15):3539-3549. PubMed ID: 29691297
[No Abstract] [Full Text] [Related]
10. Development and Validation of StrataNGS, a Multiplex PCR, Semiconductor Sequencing-Based Comprehensive Genomic Profiling Test.
Tomlins SA; Hovelson DH; Harms P; Drewery S; Falkner J; Fischer A; Hipp J; Kwiatkowski K; Lazo de la Vega L; Mitchell K; Reeder T; Siddiqui J; Vakil H; Johnson DB; Rhodes DR
J Mol Diagn; 2021 Nov; 23(11):1515-1533. PubMed ID: 34454112
[TBL] [Abstract][Full Text] [Related]
11. Validation of the Labcorp Plasma Focus Test to Facilitate Precision Oncology Through Cell-Free DNA Genomic Profiling of Solid Tumors.
Verner EL; Jackson JB; Severson E; Valkenburg KC; Greer AE; Riley DR; Sausen M; Maddox C; McGregor PM; Karandikar A; Hastings SB; Previs RA; Reddy VP; Jensen TJ; Ramkissoon SH
J Mol Diagn; 2023 Jul; 25(7):477-489. PubMed ID: 37068734
[TBL] [Abstract][Full Text] [Related]
12. Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology.
Husain H; Nykin D; Bui N; Quan D; Gomez G; Woodward B; Venkatapathy S; Duttagupta R; Fung E; Lippman SM; Kurzrock R
Mol Cancer Ther; 2017 May; 16(5):948-955. PubMed ID: 28468865
[TBL] [Abstract][Full Text] [Related]
13. Using circulating cell-free DNA to monitor personalized cancer therapy.
Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
[TBL] [Abstract][Full Text] [Related]
14. Automated next-generation profiling of genomic alterations in human cancers.
Keefer LA; White JR; Wood DE; Gerding KMR; Valkenburg KC; Riley D; Gault C; Papp E; Vollmer CM; Greer A; Hernandez J; McGregor PM; Zingone A; Ryan BM; Deak K; McCall SJ; Datto MB; Prescott JL; Thompson JF; Cerqueira GC; Jones S; Simmons JK; McElhinny A; Dickey J; Angiuoli SV; Diaz LA; Velculescu VE; Sausen M
Nat Commun; 2022 May; 13(1):2830. PubMed ID: 35595835
[TBL] [Abstract][Full Text] [Related]
15. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA.
Chae YK; Davis AA; Carneiro BA; Chandra S; Mohindra N; Kalyan A; Kaplan J; Matsangou M; Pai S; Costa R; Jovanovic B; Cristofanilli M; Platanias LC; Giles FJ
Oncotarget; 2016 Oct; 7(40):65364-65373. PubMed ID: 27588476
[TBL] [Abstract][Full Text] [Related]
16. Detection of Circulating Tumor DNA with a Single-Molecule Sequencing Analysis Validated for Targeted and Immunotherapy Selection.
Atkins A; Gupta P; Zhang BM; Tsai WS; Lucas J; Javey M; Vora A; Mei R
Mol Diagn Ther; 2019 Aug; 23(4):521-535. PubMed ID: 31209714
[TBL] [Abstract][Full Text] [Related]
17. Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy.
Li G; Pavlick D; Chung JH; Bauer T; Tan BA; Peguero J; Ward P; Kallab A; Bufill J; Hoffman A; Sadiq A; Edenfield J; He J; Cooke M; Hughes J; Forcier B; Nahas M; Stephens P; Ali SM; Schrock AB; Ross JS; Miller VA; Gregg JP
J Gastrointest Oncol; 2019 Oct; 10(5):831-840. PubMed ID: 31602320
[TBL] [Abstract][Full Text] [Related]
18. Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients.
Keup C; Benyaa K; Hauch S; Sprenger-Haussels M; Tewes M; Mach P; Bittner AK; Kimmig R; Hahn P; Kasimir-Bauer S
Cell Mol Life Sci; 2020 Feb; 77(3):497-509. PubMed ID: 31254045
[TBL] [Abstract][Full Text] [Related]
19. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer.
Schrock AB; Welsh A; Chung JH; Pavlick D; Bernicker EH; Creelan BC; Forcier B; Ross JS; Stephens PJ; Ali SM; Dagogo-Jack I; Shaw AT; Li T; Ou SI; Miller VA
J Thorac Oncol; 2019 Feb; 14(2):255-264. PubMed ID: 30368012
[TBL] [Abstract][Full Text] [Related]
20. Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.
Du M; Thompson J; Fisher H; Zhang P; Huang CC; Wang L
Lung Cancer; 2018 Jun; 120():113-121. PubMed ID: 29748005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]